We recently published our article 10 Stocks Under $10 Analysts Believe Could Soar 200%. In this article, we discuss AtaiBeckley N.V. (NASDAQ:ATAI) as one of the stocks gaining attention, and here’s a closer look at why it stands out in today’s market.

Stocks trading below $10 have always attracted investors looking for outsized returns. The appeal is easy to understand: a stock rising from $5 to $15 delivers a 200% gain, meaning the investment triples in value. However, a low share price does not automatically mean a company is cheap.

One useful piece of market trivia is that share price and company size are not the same thing. A stock trading at $6 can still represent a multibillion-dollar business if the company has hundreds of millions of shares outstanding. That is why investors searching for the best stocks under $10 should also examine market capitalization, revenue growth, profitability, debt, cash flow, and long-term business prospects.

The companies featured in this article are not small penny stocks. Each has a market capitalization of more than $2 billion and carries a consensus analyst price target suggesting at least 200% upside.

Small-Cap Stocks Are Gaining Momentum

The search for 10 stocks under $10 that could soar 200% comes as smaller companies begin outperforming the broader U.S. stock market.

On July 2, Dominic Pappalardo, Chief Multi-Asset Strategist at Morningstar Wealth, said small-cap stocks could continue delivering above-market returns because their valuations remain attractive compared with large-cap shares.

During 2026, the Morningstar U.S. Small Cap Market Index gained 14%, outperforming the 10.7% increase recorded by the broader Morningstar U.S. Market.

This performance is notable because U.S. small-cap stocks have generally lagged their mid-cap and large-cap peers over the past 15 years. That prolonged underperformance has left many smaller companies trading at discounted valuations, creating potential opportunities for investors looking for undervalued stocks under $10.

The small-cap rally has continued despite a volatile year shaped by geopolitical tensions, including the Iran-U.S. conflict. Latin American stocks have also performed well since the beginning of the war, supported partly by the region’s exposure to oil and other commodities.

Small Caps May Offer Better Diversification

Pappalardo also pointed to diversification as another reason investors may consider small-cap stocks.

Although the S&P 500 includes around 500 companies, approximately 40% of the index is concentrated in its 10 largest holdings. This means a relatively small group of mega-cap companies can have an enormous influence on the performance of the broader market.

Small-cap indexes are generally less concentrated. Their performance is spread across a wider range of industries, including healthcare, financial services, industrials, energy, consumer products, and technology.

This broader exposure could appeal to investors who believe the market has become too dependent on a handful of large technology companies. It may also create opportunities to find high-upside stocks under $10 that are overlooked by investors focused primarily on the biggest names on Wall Street.

Why Stocks Under $10 Can Produce Large Returns

Low-priced stocks can generate dramatic percentage gains because even a relatively small dollar increase can translate into a large return.

For example, a stock rising from $3 to $6 doubles in value. If it reaches $9, it produces a 200% gain. However, the same mathematics also works in reverse. A decline from $6 to $3 results in a 50% loss.

That is why stocks with triple-digit upside potential usually come with considerable risk. A depressed stock price may reflect temporary market pessimism, but it can also signal weak earnings, high debt, slowing demand, regulatory problems, or uncertainty surrounding the company’s business model.

Analyst price targets should therefore be treated as research tools rather than guarantees. A consensus estimate showing 200% upside means analysts see significant recovery potential, but the company may still need to meet ambitious revenue, earnings, or operational expectations.

Small-Cap Valuations Remain Appealing

Morningstar Wealth believes small-cap stocks are more undervalued than they have been in years, while large-cap stocks currently appear expensive.

That valuation gap could support further gains if investors begin shifting money away from highly valued mega-cap stocks and toward smaller companies with stronger recovery potential.

Still, not every inexpensive stock will become a winner. The strongest opportunities may be found in companies with improving fundamentals, manageable debt, competitive advantages, and identifiable growth catalysts.

With that background, let’s examine the 10 stocks under $10 that could soar 200%.

CHECK THIS OUT: Top 10 Stocks That Could Make You a Millionaire Over the Next 3 Years andTop 10 Cheap Stocks Under $10 To Buy Now.

Our Methodology

In order to come up with our list of the 10 stocks under $10 that could soar 200%, we screened U.S.-listed stocks trading below $10 with market capitalizations above $2 billion, shortlisted those with at least 200% consensus upside as of the July 10 close, and ranked the 10 qualifying companies in ascending order based on their projected upside.

10 Stocks Under $10 Analysts Believe Could Soar 200%

7. AtaiBeckley N.V. (NASDAQ:ATAI)

AtaiBeckley N.V. (NASDAQ: ATAI) ranks seventh among the best stocks under $10 that could triple, with shares recently trading near $7.20 after advancing 0.70%. The company is developing a portfolio of mental health treatments, including therapies for treatment-resistant depression, major depressive disorder, generalized anxiety disorder, alcohol-use disorder, and cognitive impairment associated with schizophrenia.

On June 25, AtaiBeckley N.V. (NASDAQ: ATAI) announced that its shares would be added to the Russell 2000 Index and Russell 3000 Index as part of the latest annual index reconstitution. The inclusion became effective on June 29.

Russell index membership may appear technical, but it can have meaningful consequences for a small-cap stock. Investment funds and exchange-traded funds that track Russell benchmarks may need to purchase shares of newly included companies to keep their portfolios aligned with the index. This can improve trading liquidity, expand institutional ownership, and introduce the company to a wider group of professional investors.

AtaiBeckley N.V. (NASDAQ: ATAI) emphasized that more than $12 trillion in assets are benchmarked against Russell indexes. The Russell 2000 tracks approximately 2,000 smaller publicly traded companies, while the Russell 3000 represents around 3,000 companies across the small-cap, mid-cap, and large-cap segments of the U.S. equity market.

Index inclusion does not change a company’s scientific prospects or guarantee that its share price will rise. Nevertheless, it can strengthen market visibility at an important stage in the company’s development. Biotechnology companies regularly need access to capital, and a broader institutional audience can potentially support future financing activity.

The larger catalyst came on July 7, when Canaccord Genuity raised its price target for AtaiBeckley N.V. (NASDAQ: ATAI) from $15 to $17 and reaffirmed its Buy rating. Based on the referenced trading level, the updated target suggested upside of more than 227%.

The target increase followed the company’s announcement that dosing had been completed for the final patient in its Phase 2 Elumina trial evaluating VLS-01 for treatment-resistant depression. Completion of patient dosing is a key operational milestone because it moves a clinical program closer to data collection, analysis, and eventual results.

VLS-01 is being studied as a treatment for patients whose depression has not responded adequately to conventional therapies. Treatment-resistant depression represents one of the most difficult areas of psychiatric medicine. Many patients cycle through multiple antidepressants, combinations, and therapeutic approaches without achieving lasting relief.

AtaiBeckley N.V. (NASDAQ: ATAI) is ultimately targeting Phase 3 development for major depressive disorder. The company may also investigate opportunities in generalized anxiety disorder, potentially expanding the addressable market for the program.

The company operates in a highly visible but controversial area of biotechnology. Several developers are studying psychedelic-derived or altered-state therapies for mental health conditions. Supporters believe these treatments could provide rapid and durable benefits for patients who have not responded to existing medications. Critics point to questions involving safety, treatment supervision, trial design, durability of benefit, manufacturing, regulatory standards, and real-world implementation.

For AtaiBeckley N.V. (NASDAQ: ATAI), the opportunity is therefore larger than simply developing another antidepressant. The company is attempting to help establish a new treatment model for serious psychiatric disorders. Successful results could attract significant investor, medical, and pharmaceutical interest. Weak data, regulatory resistance, or difficulties integrating the therapy into clinical practice could have the opposite effect.

AtaiBeckley N.V. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company engaged in researching, developing, and potentially commercializing therapies for mental health conditions. Its product pipeline includes BPL-003, which is being studied in Phase 2 trials for treatment-resistant depression and alcohol-use disorder, as well as RL-007, which is being developed for cognitive impairment associated with schizophrenia.

A diversified pipeline can reduce dependence on a single drug, but it also requires considerable funding. Each clinical program involves separate trial costs, regulatory discussions, manufacturing preparation, intellectual-property management, and commercialization planning.

Investors will therefore need to watch the company’s cash runway and capital-allocation decisions alongside its clinical results. A biotechnology company can produce encouraging data and still struggle if it must raise money under unfavorable market conditions. Conversely, successful clinical milestones can improve financing terms and attract strategic partners.

The inclusion of AtaiBeckley N.V. (NASDAQ: ATAI) in major Russell indexes may support trading liquidity and institutional awareness, while the Canaccord Genuity price-target increase demonstrates strong analyst confidence in the company’s development strategy. However, the stock’s projected upside remains dependent on clinical evidence.

For investors searching for mental health stocks, psychedelic biotech stocks, depression treatment stocks, and speculative stocks under $10 with triple-digit analyst upside, AtaiBeckley N.V. (NASDAQ: ATAI) offers a distinctive opportunity. It also carries the substantial risks that come with clinical-stage drug development and the regulatory complexity of emerging psychiatric therapies.

YOU MUST READ THIS: 10 Robotics Stocks to Buy Now as Amazon (AMZN) Hits 1M Robots

Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.